ELF4

Across TCGA pan-cancer cohorts, ELF4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELF4 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ELF4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ELF4 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where ELF4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.887	0.432	<.001	26	view →
HNSC	DFS	Median	All	0.271	0.860	.038	6	view →
LSCC	DFS	Tertile	All	0.641	0.879	.020	5	view →
LUAD	DFS	Median	III,IV	0.315	0.948	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELF4–PDAC (DFS)

Open the PDAC breakdown →